Related Experiment Video
Updated: Oct 3, 2025
Murine Model of CD40-activation of B cells
Published on: March 5, 2010
Characterization of the canine CD20 as a therapeutic target for comparative passive immunotherapy
Joana N R Dias1, André Almeida1, Ana S André1
1CIISA-Centro de Investigação Interdisciplinar em Sanidade Animal, Faculdade de Medicina Veterinária, Universidade de Lisboa, 1300-477, Lisbon, Portugal.
Abstract:
Anti-CD20 therapies have revolutionized the treatment of B-cell malignancies. Despite these advances, relapsed and refractory disease remains a major treatment challenge. The optimization of CD20-targeted immunotherapies is considered a promising strategy to improve current therapies. However, research has been limited by the scarcity of preclinical models that recapitulate the complex interaction between the immune system and cancers. The addition of the canine lymphoma (cNHL) model in the development of anti-CD20 therapies may provide a clinically relevant approach for the translation of improved immunotherapies. Still, an anti-CD20 therapy for cNHL has not been established stressing the need of a comprehensive target characterization. Herein, we performed an in-depth characterization on canine CD20 mRNA transcript and protein expression in a cNHL biobank and demonstrated a canine CD20 overexpression in B-cell lymphoma samples. Moreover, CD20 gene sequencing analysis identified six amino acid differences in patient samples (C77Y, L147F, I159M, L198V, A201T and G273E). Finally, we reported the use of a novel strategy for the generation of anti-CD20 mAbs, with human and canine cross-reactivity, by exploring our rabbit derived single-domain antibody platform. Overall, these results support the rationale of using CD20 as a target for veterinary settings and the development of novel therapeutics and immunodiagnostics.
Insights
Canine lymphoma (cNHL) shows CD20 overexpression, supporting its use as a therapeutic target. This study characterized canine CD20 and developed cross-reactive antibodies for novel veterinary immunotherapies.
Area of Science:
- Immunology
- Veterinary Medicine
- Oncology
Background:
- Anti-CD20 therapies are vital for B-cell malignancies but face challenges with relapsed/refractory disease.
- Preclinical models are scarce, limiting the optimization of CD20-targeted immunotherapies.
- Canine lymphoma (cNHL) offers a potential preclinical model, but anti-CD20 therapies are not established.
Purpose of the Study:
- To characterize canine CD20 (cCD20) expression and sequence in cNHL.
- To develop novel anti-CD20 monoclonal antibodies (mAbs) with cross-reactivity for canine and human applications.
- To support CD20 as a viable target for veterinary therapeutics and immunodiagnostics.
Main Methods:
- In-depth characterization of canine CD20 mRNA and protein expression in a cNHL biobank.
- CD20 gene sequencing analysis in patient samples.
- Generation of anti-CD20 mAbs using a rabbit-derived single-domain antibody platform.
Main Results:
- Demonstrated significant canine CD20 overexpression in B-cell lymphoma samples.
- Identified six amino acid differences in canine CD20 compared to human.
- Successfully generated novel anti-CD20 mAbs with both human and canine cross-reactivity.
Conclusions:
- Canine CD20 is a promising target for developing new immunotherapies in veterinary oncology.
- The characterized cCD20 and novel mAbs pave the way for improved treatments and diagnostics for canine lymphoma.
- This research supports the translation of CD20-targeted strategies to veterinary settings.
Related Concept Videos
01:27Tumor Immunotherapy
01:22T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...